Dissident AIDS Database

HIV drugsAZT/PIsSide effectsNeutropenia
Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1.
 Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, Berrebi A, Benifla JL, Burgard M, Lachassine E, Barret B, Chaix ML, Bongain A, Ciraru-Vigneron N, Crenn-Hebert C, Delfraissy JF, Rouzioux C, Mayaux MJ, Blanche S; Agence Nationale de Recherches sur le SIDA (ANRS) 075 Study Group.
  "To assess the safety of perinatal lamivudine-zidovudine therapy, especially in children, and its effects on viral load, acquisition of drug resistance, and maternal-infant transmission of HIV-1 in a nonbreastfeeding population... A total of 445 HIV-1-infected pregnant women were enrolled as the study cohort from February 1997 to September 1998; controls consisted of 899 pregnant women who had received zidovudine monotherapy in May 1994 to February 1997 as standard care. The study cohort received lamivudine in addition to the standard Pediatric AIDS Clinical Trial Group 076 Study zidovudine prophylaxis regimen... The most frequent serious adverse events in children were neutropenia ... requiring blood transfusion in 9 children and premature treatment discontinuation in 19. Two uninfected children died at age 1 year from neurologic complications related to mitochondrial dysfunction."
  JAMA 2001 Apr 25;285(16):2083-932001
Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection.
 Pizzo PA et al.
  “Transfusion was required in 14 patients because of low levels of hemoglobin. Dose-limiting neutropenia occurred in most patients who received doses of 1.4 mg per kilogram per hour or more...The major limitation of the therapy was hematologic toxicity--a decrease in both the hemoglobin concentration and the white-cell count...Regardless of the starting dose, nearly all patients had a transient drop in their neutrophil counts within 10 days of the initiation of AZT therapy...”
  NEJM. 1988;319:889-96.1988
Side effects of AZT prophylaxis after occupational exposure to HIV-infected blood.
 Schmitz SH, Scheding S, Voliotis D, Rasokat H, Diehl V, Schrappe M
  AZT was given to 14 health care workers who had been exposed to HIV-contaminated blood through needle sticks and similar accidents. None of the 14 workers actually became HIV-positive as a result of their needle stick (which is not surprising since the likelihood of contracting HIV is estimated at about 1 in 333). Only 11 of the 14 people could continue to take the drug for more than four weeks. The three people who could not make it to four weeks dropped out due to "severe subjective symptoms". Neutropenia developed in 36% (4 of 11) of the people who completed 4 weeks of AZT treatment. Fully half of the 14 workers had to quit the drug because of severe toxic effects, and the study was stopped early because of these effects.
  Annals of Hematology; 69:135-138, (1994).1994